{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:17:25Z","timestamp":1787008645893,"version":"build-2736575974"},"reference-count":46,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2024,3,31]],"date-time":"2024-03-31T00:00:00Z","timestamp":1711843200000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"name":"John Perrett Bequest Funding Scheme"},{"DOI":"10.13039\/100008717","name":"Viertel Charitable Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008717","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,6,3]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>This study investigated whether parathyroid hormone (PTH) lowering with etelcalcetide, and the consequent effects on mineral and bone metabolism, could improve serum calcification propensity (T50 time) and decrease calciprotein particle (CPP) load in hemodialysis patients with secondary hyperparathyroidism.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this single-arm, prospective, dose-escalation proof-of-principle study, hemodialysis patients received etelcalcetide at 2.5\u00a0mg\/dialysis session with increments of 2.5\u00a0mg every 4 weeks to a maximum dose of 15\u00a0mg three times a week or until a pre-specified safety endpoint was reached, followed by an 8-week wash-out phase.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Out of 36 patients recruited (81% male, 62\u00a0\u00b1\u00a013 years), 16 patients completed the study per protocol with a mean maximum tolerated dose of etelcalcetide of 9.5\u00a0\u00b1\u00a02.9\u00a0mg\/dialysis session. With escalating doses of etelcalcetide, PTH and serum calcium levels significantly decreased (P\u00a0&amp;lt;\u00a00.0001). While there was no significant change in T50 times or serum phosphate levels, etelcalcetide did yield significant and consistent reductions in serum levels of endogenous calciprotein monomers [\u221235.4 (\u221244.4 to \u221226.5)%, P\u00a0&amp;lt;\u00a00.0001], primary [\u221222.4 (\u221234.5 to \u221210.3)%, P\u00a0&amp;lt;\u00a00.01] and secondary CPP [\u221229.1 (\u221245.7 to \u221212.4)%, P\u00a0&amp;lt;\u00a00.01], an effect that was reversed after therapy withdrawal. Serum levels of osteoclastic markers significantly decreased with escalating doses of etelcalcetide, while levels of the osteoblastic marker remained stable.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Lowering of PTH with etelcalcetide did not result in statistically significant changes in T50. By contrast, homogenous reductions in serum levels of calciprotein monomers, primary and secondary CPP were observed.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ckj\/sfae097","type":"journal-article","created":{"date-parts":[[2024,3,29]],"date-time":"2024-03-29T18:58:43Z","timestamp":1711738723000},"source":"Crossref","is-referenced-by-count":8,"title":["The effect of parathyroid hormone lowering by etelcalcetide therapy on calcification propensity and calciprotein particles in hemodialysis patients"],"prefix":"10.1093","volume":"17","author":[{"given":"Ursula","family":"Thiem","sequence":"first","affiliation":[{"name":"Department of Medicine III - Nephrology, Hypertension, Transplantation Medicine, Rheumatology, Geriatrics, Ordensklinikum Linz - Elisabethinen Hospital , Linz , Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakob","family":"Lenz","sequence":"additional","affiliation":[{"name":"Department of Medicine III - Nephrology, Hypertension, Transplantation Medicine, Rheumatology, Geriatrics, Ordensklinikum Linz - Elisabethinen Hospital , Linz , Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria C","family":"Haller","sequence":"additional","affiliation":[{"name":"Department of Medicine III - Nephrology, Hypertension, Transplantation Medicine, Rheumatology, Geriatrics, Ordensklinikum Linz - Elisabethinen Hospital , Linz , Austria"},{"name":"CeMSIIS - Center for Medical Statistics, Informatics, and Intelligent Systems, Medical University Vienna , Vienna , Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Pasch","sequence":"additional","affiliation":[{"name":"Calciscon AG , Biel , Switzerland"},{"name":"Lindenhofspital Bern , Bern , Switzerland"},{"name":"Department of Physiology and Pathophysiology, Johannes Kepler University Linz , Linz , Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward R","family":"Smith","sequence":"additional","affiliation":[{"name":"Department of Nephrology, The Royal Melbourne Hospital , Parkville, Victoria , Australia"},{"name":"Department of Medicine (RMH), The University of Melbourne , Parkville, Victoria , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Cejka","sequence":"additional","affiliation":[{"name":"Department of Medicine III - Nephrology, Hypertension, Transplantation Medicine, Rheumatology, Geriatrics, Ordensklinikum Linz - Elisabethinen Hospital , Linz , Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,3,30]]},"reference":[{"key":"2024062514522852600_bib1","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1097\/01.ASN.0000133041.27682.A2","article-title":"Mineral metabolism, mortality, and morbidity in maintenance hemodialysis","volume":"15","author":"Block","year":"2004","journal-title":"J Am Soc Nephrol"},{"key":"2024062514522852600_bib2","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1053\/j.ajkd.2008.03.020","article-title":"Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS)","volume":"52","author":"Tentori","year":"2008","journal-title":"Am J Kidney Dis"},{"key":"2024062514522852600_bib3","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1093\/ndt\/gfq219","article-title":"Serum iPTH, calcium and phosphate, and the risk of mortality in a European haemodialysis population","volume":"26","author":"Floege","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"2024062514522852600_bib4","first-page":"S1","article-title":"KDIGO Clinical Practice Guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD)","year":"2009","journal-title":"Kidney Int Suppl"},{"key":"2024062514522852600_bib5","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1001\/jama.2016.19456","article-title":"Effect of etelcalcetide vs placebo on serum parathyroid hormone in patients receiving hemodialysis with secondary hyperparathyroidism: two randomized clinical trials","volume":"317","author":"Block","year":"2017","journal-title":"JAMA"},{"key":"2024062514522852600_bib6","first-page":"1723","article-title":"A phase 3, multicentre, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of etelcalcetide (ONO-5163\/AMG 416), a novel intravenous calcimimetic, for secondary hyperparathyroidism in Japanese haemodialysis patients","volume":"32","author":"Fukagawa","year":"2017","journal-title":"Nephrol Dial Transplant"},{"key":"2024062514522852600_bib7","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1001\/jama.2016.19468","article-title":"Effect of Etelcalcetide vs cinacalcet on serum parathyroid hormone in patients receiving hemodialysis with secondary hyperparathyroidism: a randomized clinical trial","volume":"317","author":"Block","year":"2017","journal-title":"JAMA"},{"key":"2024062514522852600_bib8","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1681\/ASN.2012030240","article-title":"Nanoparticle-based test measures overall propensity for calcification in serum","volume":"23","author":"Pasch","year":"2012","journal-title":"J Am Soc Nephrol"},{"key":"2024062514522852600_bib9","doi-asserted-by":"crossref","first-page":"315","DOI":"10.2215\/CJN.04720416","article-title":"Blood calcification propensity, cardiovascular events, and survival in patients receiving hemodialysis in the EVOLVE trial","volume":"12","author":"Pasch","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"key":"2024062514522852600_bib10","doi-asserted-by":"crossref","first-page":"5686","DOI":"10.1038\/s41598-017-05474-y","article-title":"A novel fluorescent probe-based flow cytometric assay for mineral-containing nanoparticles in serum","volume":"7","author":"Smith","year":"2017","journal-title":"Sci Rep"},{"key":"2024062514522852600_bib11","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1093\/ndt\/gfac271","article-title":"Effect of the phosphate binder sucroferric oxyhydroxide in dialysis patients on endogenous calciprotein particles, inflammation, and vascular cells","volume":"38","author":"Thiem","year":"2023","journal-title":"Nephrol Dial Transplant"},{"key":"2024062514522852600_bib12","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.atherosclerosis.2020.03.016","article-title":"Mid-term predictive value of calciprotein particles in maintenance hemodialysis patients based on a gel-filtration assay","volume":"303","author":"Gatate","year":"2020","journal-title":"Atherosclerosis"},{"key":"2024062514522852600_bib13","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.3389\/fimmu.2018.01991","article-title":"Cellular clearance and biological activity of calciprotein particles depend on their maturation state and crystallinity","volume":"9","author":"Koppert","year":"2018","journal-title":"Front. Immunol"},{"key":"2024062514522852600_bib14","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.atherosclerosis.2016.05.044","article-title":"Calcification of vascular smooth muscle cells is induced by secondary calciprotein particles and enhanced by tumor necrosis factor-\u03b1","volume":"251","author":"Aghagolzadeh","year":"2016","journal-title":"Atherosclerosis"},{"key":"2024062514522852600_bib15","doi-asserted-by":"crossref","first-page":"12458","DOI":"10.3390\/ijms222212458","article-title":"Calciprotein particles link disturbed mineral homeostasis with cardiovascular disease by causing endothelial dysfunction and vascular inflammation","volume":"22","author":"Shishkova","year":"2021","journal-title":"Int J Mol Sci"},{"key":"2024062514522852600_bib16","doi-asserted-by":"crossref","first-page":"14941","DOI":"10.3390\/ijms232314941","article-title":"Calciprotein particles cause physiologically significant pro-inflammatory response in endothelial cells and systemic circulation","volume":"23","author":"Shishkova","year":"2022","journal-title":"Int J Mol Sci"},{"key":"2024062514522852600_bib17","doi-asserted-by":"crossref","first-page":"e60904","DOI":"10.1371\/journal.pone.0060904","article-title":"Fetuin-A-containing calciprotein particles reduce mineral stress in the macrophage","volume":"8","author":"Smith","year":"2013","journal-title":"PLoS ONE"},{"key":"2024062514522852600_bib18","doi-asserted-by":"crossref","first-page":"948177","DOI":"10.3389\/fmed.2022.948177","article-title":"Bone specific alkaline phosphatase and serum calcification propensity are not influenced by etelcalcetide vs. alfacalcidol treatment, and only bone specific alkaline phosphatase is correlated with fibroblast growth factor 23: sub-analysis results of the ETACAR-HD Study","volume":"9","author":"Dorr","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"2024062514522852600_bib19","doi-asserted-by":"crossref","first-page":"599","DOI":"10.2215\/CJN.16601020","article-title":"Comparative effects of etelcalcetide and maxacalcitol on serum calcification propensity in secondary hyperparathyroidism: a randomized clinical trial","volume":"16","author":"Shoji","year":"2021","journal-title":"Clin J Am Soc Nephrol"},{"key":"2024062514522852600_bib20","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1093\/ckj\/sfaa154","article-title":"The effect of phosphate binder therapy with sucroferric oxyhydroxide on calcification propensity in chronic haemodialysis patients: a randomized, controlled, crossover trial","volume":"14","author":"Thiem","year":"2021","journal-title":"Clin Kidney J"},{"key":"2024062514522852600_bib21","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1097\/01.ASN.0000129337.50739.48","article-title":"Arterial calcifications and bone histomorphometry in end-stage renal disease","volume":"15","author":"London","year":"2004","journal-title":"J Am Soc Nephrol"},{"key":"2024062514522852600_bib22","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1093\/ndt\/gfv099","article-title":"Improvement of mineral and bone metabolism markers is associated with better survival in haemodialysis patients: the COSMOS study","volume":"30","author":"Fernandez-Martin","year":"2015","journal-title":"Nephrol. Dial. Transplant"},{"key":"2024062514522852600_bib23","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1053\/ajkd.2000.19812","article-title":"Increased incidence of hip fractures in dialysis patients with low serum parathyroid hormone","volume":"36","author":"Coco","year":"2000","journal-title":"Am J Kidney Dis"},{"key":"2024062514522852600_bib24","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.kint.2017.04.006","article-title":"Executive summary of the 2017 KDIGO Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Guideline Update: what's changed and why it matters","volume":"92","author":"Ketteler","year":"2017","journal-title":"Kidney Int"},{"key":"2024062514522852600_bib25","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1186\/s12882-018-0910-9","article-title":"Longitudinal changes in bone and mineral metabolism after cessation of cinacalcet in dialysis patients with secondary hyperparathyroidism","volume":"19","author":"Ruderman","year":"2018","journal-title":"BMC Nephrol"},{"key":"2024062514522852600_bib26","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1111\/nep.14081","article-title":"Impact of etelcalcetide on fibroblast growth factor-23 and calciprotein particles in patients with secondary hyperparathyroidism undergoing haemodialysis","volume":"27","author":"Hashimoto","year":"2022","journal-title":"Nephrology"},{"key":"2024062514522852600_bib27","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1016\/j.ekir.2020.09.010","article-title":"A prospective, randomized clinical trial of etelcalcetide in patients receiving hemodialysis with secondary hyperparathyroidism (the DUET Trial)","volume":"5","author":"Itano","year":"2020","journal-title":"Kidney Int Rep"},{"key":"2024062514522852600_bib28","doi-asserted-by":"crossref","first-page":"286","DOI":"10.3747\/pdi.2017.00163","article-title":"Calciprotein particle formation in peritoneal dialysis effluent is dependent on dialysate calcium concentration","volume":"38","author":"Cai","year":"2018","journal-title":"Perit Dial Int"},{"key":"2024062514522852600_bib29","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1056\/NEJMoa1205624","article-title":"Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis","volume":"367","author":"Chertow","year":"2012","journal-title":"N Engl J Med"},{"key":"2024062514522852600_bib30","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1093\/ndt\/gfz060","article-title":"Association of changes in bone mineral parameters with mortality in haemodialysis patients: insights from the ARO cohort","volume":"35","author":"Lamina","year":"2020","journal-title":"Nephrol Dial Transplant"},{"key":"2024062514522852600_bib31","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.2215\/CJN.03270314","article-title":"Effect of cinacalcet and vitamin D analogs on fibroblast growth factor-23 during the treatment of secondary hyperparathyroidism","volume":"10","author":"Sprague","year":"2015","journal-title":"Clin J Am Soc Nephrol"},{"key":"2024062514522852600_bib32","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1016\/j.clinthera.2018.10.016","article-title":"Effects of the intravenous calcimimetic etelcalcetide on bone turnover and serum fibroblast growth factor 23: post hoc analysis of an open-label study","volume":"40","author":"Shigematsu","year":"2018","journal-title":"Clin Ther"},{"key":"2024062514522852600_bib33","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1007\/s11255-011-0050-7","article-title":"Cinacalcet lowers FGF-23 level together with bone metabolism in hemodialyzed patients with secondary hyperparathyroidism","volume":"44","author":"Hryszko","year":"2012","journal-title":"Int Urol Nephrol"},{"key":"2024062514522852600_bib34","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1161\/CIRCULATIONAHA.114.013876","article-title":"Cinacalcet, fibroblast growth factor-23, and cardiovascular disease in hemodialysis: the Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial","volume":"132","author":"Moe","year":"2015","journal-title":"Circulation"},{"key":"2024062514522852600_bib35","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1359\/jbmr.2002.17.7.1171","article-title":"Bone origin of the serum complex of calcium, phosphate, fetuin, and matrix Gla protein: biochemical evidence for the cancellous bone-remodeling compartment","volume":"17","author":"Price","year":"2002","journal-title":"J Bone Min Res"},{"key":"2024062514522852600_bib36","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.kint.2019.10.019","article-title":"Calciprotein particles regulate fibroblast growth factor-23 expression in osteoblasts","volume":"97","author":"Akiyama","year":"2020","journal-title":"Kidney Int"},{"key":"2024062514522852600_bib37","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s11914-023-00782-x","article-title":"Impact of cinacalcet and etelcalcetide on bone mineral and cardiovascular disease in dialysis patients","volume":"21","author":"Bernardor","year":"2023","journal-title":"Curr Osteoporos Rep"},{"key":"2024062514522852600_bib38","doi-asserted-by":"crossref","first-page":"7358","DOI":"10.1038\/s41598-022-11065-3","article-title":"Effect of nutritional calcium and phosphate loading on calciprotein particle kinetics in adults with normal and impaired kidney function","volume":"12","author":"Tiong","year":"2022","journal-title":"Sci Rep"},{"key":"2024062514522852600_bib39","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1093\/ndt\/gfr609","article-title":"Phosphorylated fetuin-A-containing calciprotein particles are associated with aortic stiffness and a procalcific milieu in patients with pre-dialysis CKD","volume":"27","author":"Smith","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"2024062514522852600_bib40","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1681\/ASN.2009090944","article-title":"Fetuin-mineral complex reflects extraosseous calcification stress in CKD","volume":"21","author":"Hamano","year":"2010","journal-title":"J Am Soc Nephrol"},{"key":"2024062514522852600_bib41","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.jjcc.2019.04.008","article-title":"Association of calciprotein particles measured by a new method with coronary artery plaque in patients with coronary artery disease: a cross-sectional study","volume":"74","author":"Nakazato","year":"2019","journal-title":"J Cardiol"},{"key":"2024062514522852600_bib42","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1681\/ASN.2013060635","article-title":"Serum calcification propensity predicts all-cause mortality in predialysis CKD","volume":"25","author":"Smith","year":"2014","journal-title":"J Am Soc Nephrol"},{"key":"2024062514522852600_bib43","first-page":"1","article-title":"Parathyroid hormone fragments: new targets for the diagnosis and treatment of chronic kidney disease-mineral and bone disorder","volume":"2018","author":"Chen","year":"2018","journal-title":"Biomed Res Int"},{"key":"2024062514522852600_bib44","doi-asserted-by":"crossref","first-page":"4744","DOI":"10.1210\/jc.2013-2139","article-title":"Nonoxidized, biologically active parathyroid hormone determines mortality in hemodialysis patients","volume":"98","author":"Tepel","year":"2013","journal-title":"J Clin Endocrinol Metabol"},{"key":"2024062514522852600_bib45","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1093\/oxfordjournals.ndt.a027089","article-title":"PTH\/PTHrP receptor mRNA is down-regulated in epiphyseal cartilage growth plate of uraemic rats","volume":"11","author":"Ure\u00f1a","year":"1996","journal-title":"Nephrol Dial Transplant"},{"key":"2024062514522852600_bib46","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1038\/sj.ki.5002769","article-title":"K\/DOQI-recommended intact PTH levels do not prevent low-turnover bone disease in hemodialysis patients","volume":"73","author":"Barreto","year":"2008","journal-title":"Kidney Int"}],"container-title":["Clinical Kidney Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ckj\/advance-article-pdf\/doi\/10.1093\/ckj\/sfae097\/57129009\/sfae097.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ckj\/article-pdf\/17\/6\/sfae097\/58326908\/sfae097.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ckj\/article-pdf\/17\/6\/sfae097\/58326908\/sfae097.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,25]],"date-time":"2024-06-25T11:50:48Z","timestamp":1719316248000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ckj\/article\/doi\/10.1093\/ckj\/sfae097\/7638202"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,30]]},"references-count":46,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6,3]]}},"URL":"https:\/\/doi.org\/10.1093\/ckj\/sfae097","relation":{},"ISSN":["2048-8505","2048-8513"],"issn-type":[{"value":"2048-8505","type":"print"},{"value":"2048-8513","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,6]]},"published":{"date-parts":[[2024,3,30]]},"article-number":"sfae097"}}